165 related articles for article (PubMed ID: 35655778)
1. Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.
Qian S; Ding M; Hou H; Wang Z; Zhang J; Zhang Y; Dong M; Zhu L; Wang G; Li W; Zhang X
Front Immunol; 2022; 13():899073. PubMed ID: 35655778
[TBL] [Abstract][Full Text] [Related]
2. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study.
Yu T; Cai QQ; Zhai QL; Li L; Fang X; Li J; Sun R; Yang H; Wang Z; Qian W; Xu-Monette ZY; Young KH; Yu L
Leuk Lymphoma; 2022 Dec; 63(13):3082-3091. PubMed ID: 36074798
[TBL] [Abstract][Full Text] [Related]
3. Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.
Lan X; Li Z; Zhang M
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1265-1277. PubMed ID: 29736622
[TBL] [Abstract][Full Text] [Related]
4. Hyaline vascular variant of unicentric Castleman disease of the tonsil: a case report.
Li P; Liu H; Li H; Li A; Yu G; Yin W
Diagn Pathol; 2019 Jun; 14(1):70. PubMed ID: 31253137
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.
Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902
[TBL] [Abstract][Full Text] [Related]
6. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
Sopfe J; Endres A; Campbell K; Hayes K; Trout AT; Liang X; Lorsbach R; O'Brien MM; Cost CR
Pediatr Blood Cancer; 2019 May; 66(5):e27613. PubMed ID: 30680887
[TBL] [Abstract][Full Text] [Related]
7. The full spectrum of Castleman disease: 273 patients studied over 20 years.
Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
[TBL] [Abstract][Full Text] [Related]
8. Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
Newman SK; Jayanthan RK; Mitchell GW; Carreras Tartak JA; Croglio MP; Suarez A; Liu AY; Razzo BM; Oyeniran E; Ruth JR; Fajgenbaum DC
Yale J Biol Med; 2015 Dec; 88(4):383-8. PubMed ID: 26604862
[TBL] [Abstract][Full Text] [Related]
9. Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China.
Guo M; Nong L; Wang M; Zhang Y; Wang L; Sun Y; Wang Q; Liu H; Ou J; Cen X; Ren H; Dong Y
Ann Hematol; 2024 Jan; 103(1):153-162. PubMed ID: 37749319
[TBL] [Abstract][Full Text] [Related]
10. Castleman Disease: A Multicenter Case Series from Turkey.
Gündüz E; Kırkızlar HO; Ümit EG; Karaman Gülsaran S; Özkocaman V; Özkalemkaş F; Candar Ö; Elverdi T; Küçükyurt S; Paydaş S; Çeneli Ö; Karakuş S; Maral S; Ekinci Ö; İpek Y; Kis C; Güven ZT; Akdeniz A; Celkan T; Eroğlu Küçükdiler AH; Akgün Çağlıyan G; Özçelik Şengöz C; Karataş A; Bulduk T; Özcan A; Belen Apak FB; Canbolat A; Kartal İ; Ören H; Töret E; Özdemir GN; Bakanay Öztürk ŞM
Turk J Haematol; 2022 Jun; 39(2):130-135. PubMed ID: 35176839
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.
Zhang X; Rao H; Xu X; Li Z; Liao B; Wu H; Li M; Tong X; Li J; Cai Q
Cancer Sci; 2018 Jan; 109(1):199-206. PubMed ID: 29124835
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Galicier L; Schleinitz N
Rev Med Interne; 2022 Dec; 43(10S1):10S26-10S33. PubMed ID: 36657940
[TBL] [Abstract][Full Text] [Related]
13. Castleman Disease.
Wang W; Medeiros LJ
Surg Pathol Clin; 2019 Sep; 12(3):849-863. PubMed ID: 31352991
[TBL] [Abstract][Full Text] [Related]
14. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
[TBL] [Abstract][Full Text] [Related]
15. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients.
Borocco C; Ballot-Schmit C; Ackermann O; Aladjidi N; Delaleu J; Giacobbi-Milet V; Jannier S; Jeziorski E; Maurier F; Perel Y; Piguet C; Oksenhendler E; Koné-Paut I; Galeotti C
Orphanet J Rare Dis; 2020 Apr; 15(1):95. PubMed ID: 32303241
[TBL] [Abstract][Full Text] [Related]
16. A Rare Lymphoproliferative Disease: Castleman Disease.
Gündüz E; Özdemir N; Bakanay ŞM; Karakuş S
Turk J Haematol; 2021 Dec; 38(4):314-320. PubMed ID: 34719151
[TBL] [Abstract][Full Text] [Related]
17. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease.
Butzmann A; Kumar J; Sridhar K; Gollapudi S; Ohgami RS
Biology (Basel); 2021 Mar; 10(4):. PubMed ID: 33804823
[TBL] [Abstract][Full Text] [Related]
18. Unicentric Castleman disease presenting as a retroperitoneal peripancreatic mass: A report of two cases and review of literature.
Cheng JL; Cui J; Wang Y; Xu ZZ; Liu F; Liang SB; Tian H
World J Gastroenterol; 2018 Sep; 24(34):3958-3964. PubMed ID: 30228787
[TBL] [Abstract][Full Text] [Related]
19. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
[TBL] [Abstract][Full Text] [Related]
20. Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease.
Karki NR; Arfa AS; Savage N; Kutlar A
Acta Haematol; 2022; 145(2):214-220. PubMed ID: 34818661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
